AACR 2024 | Phase I trial of binimetinib and pembrolizumab in NSCLC

Natasha Leighl, MD, University of Toronto, Toronto, Canada, comments on findings from the Phase I trial (NCT03991819) of binimetinib, a MEK inhibitor, with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC). 11 patients were recruited, and were given 30mg of binimetinib twice a day over 21 days. The combination was well tolerated, with rash being the most common side effect, and patients with KRAS and BRAF mutations had the most promising responses. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.